Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on April 10, 2019, by Jaguar Health, Inc., a Delaware corporation and emerging growth company. The filing serves to correct clerical errors in a press release issued on the same date regarding the Company's fourth quarter 2019 results and activities related to Mytesi (crofelemer), its FDA-approved anti-secretory prescription drug.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corrective filing referencing a press release (Exhibit 99.1) rather than a primary financial statement containing detailed numerical data.
Material Changes
No material financial changes are detailed in this text. The primary change noted is the correction of clerical errors in the previously issued press release concerning fourth quarter 2019 results and commercial, educational, and product development activities.
Guidance, Outlook, and Risks
The filing references planned commercial, educational, and product development activities for Mytesi but does not provide specific forward-looking guidance or numerical outlooks within the text of this report. The document includes a standard disclaimer that the information is not deemed "filed" under Section 18 of the Exchange Act for liability purposes.
Key Facts for Investor Verification
- Verify the corrected financial figures and operational updates in the press release attached as Exhibit 99.1.
- Confirm the specific nature of the clerical errors corrected in the April 10, 2019 announcement.
- Review the Company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.